DrugPatentWatch Database Preview
FLONASE SENSIMIST ALLERGY RELIEF Drug Profile
see a sample report or, see our see our flat-rate plans
Which patents cover Flonase Sensimist Allergy Relief, and when can generic versions of Flonase Sensimist Allergy Relief launch?
This drug has two hundred and eighty-one patent family members in forty-one countries.
The generic ingredient in FLONASE SENSIMIST ALLERGY RELIEF is fluticasone furoate. There are twenty-six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the fluticasone furoate profile page.
Summary for FLONASE SENSIMIST ALLERGY RELIEF
| International Patents: | 281 |
| US Patents: | 8 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 3 |
| Bulk Api Vendors: | 16 |
| Patent Applications: | 520 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for FLONASE SENSIMIST ALLERGY RELIEF |
| DailyMed Link: | FLONASE SENSIMIST ALLERGY RELIEF at DailyMed |
Pharmacology for FLONASE SENSIMIST ALLERGY RELIEF
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Synonyms for FLONASE SENSIMIST ALLERGY RELIEF
| (1R,2S,8S,10S,11S,13R,14R,15S,17S)-1,8-DIFLUORO-14-{[(FLUOROMETHYL)SULFANYL]CARBONYL}-17-HYDROXY-2,13,15-TRIMETHYL-5-OXOTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADECA-3,6-DIEN-14-YL FURAN-2-CARBOXYLATE |
| (6|A,11|A,16|A,17|A)-6,9-Difluoro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioic Acid S-(Fluoromethyl) Ester |
| (6alpha,11alpha,14beta,16alpha,17alpha)-6,9-Difluoro-17-{[(Fluoromethyl)sulfanyl]carbonyl}-11-Hydroxy-16-Methyl-3-Oxoandrosta-1,4-Dien-17-Yl Furan-2-Carboxylate |
| 397864-44-7 |
| 6alpha,9-difluoro-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-11beta-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17alpha-yl 2-furoate |
| 779352-12-4 |
| 911210-90-7 |
| Alisade |
| Allermist |
| Arnuity Ellipta |
| Avamys |
| BDBM50354851 |
| CHEBI:74899 |
| DB08906 |
| DTXSID60228586 |
| Flonase Sensimist |
| Fluticasone fuorate |
| Fluticasone furancarboxylate |
| Fluticasone furoate |
| Fluticasone furoate (JAN/USAN/INN) |
| Fluticasone furoate [USAN:INN] |
| FLUTICASONEFUROATE |
| fluticasonum furoas |
| FT-0668768 |
| Furamist |
| furoate de fluticasone |
| furoato de fluticasona |
| GSK 685 698 |
| GSK 685698 |
| GW 685698 |
| GW 685698X |
| GW-685698 |
| GW-685698X |
| GW6 |
| gw685698 |
| GW685698X |
| JS86977WNV |
| PL010437 |
| SCHEMBL140504 |
| UNII-JS86977WNV |
| Veramyst |
| Veramyst (TN) |
| ZINC3992105 |
US Patents and Regulatory Information for FLONASE SENSIMIST ALLERGY RELIEF
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline Cons | FLONASE SENSIMIST ALLERGY RELIEF | fluticasone furoate | SPRAY, METERED;NASAL | 022051-002 | Aug 2, 2016 | OTC | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Glaxosmithkline Cons | FLONASE SENSIMIST ALLERGY RELIEF | fluticasone furoate | SPRAY, METERED;NASAL | 022051-002 | Aug 2, 2016 | OTC | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Glaxosmithkline Cons | FLONASE SENSIMIST ALLERGY RELIEF | fluticasone furoate | SPRAY, METERED;NASAL | 022051-002 | Aug 2, 2016 | OTC | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Glaxosmithkline Cons | FLONASE SENSIMIST ALLERGY RELIEF | fluticasone furoate | SPRAY, METERED;NASAL | 022051-002 | Aug 2, 2016 | OTC | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Non-Orange Book US Patents for FLONASE SENSIMIST ALLERGY RELIEF
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 6,777,399 | Anti-inflammatory androstane derivative compositions | ➤ Sign Up |
| 7,629,335 | Anti-inflammatory androstane derivative | ➤ Sign Up |
| 7,798,368 | Fluid dispensing device | ➤ Sign Up |
| 6,787,532 | Formulation containing anti-inflammatory androstane derivatives | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
see a sample report or, see our see our flat-rate plans
International Patents for FLONASE SENSIMIST ALLERGY RELIEF
Supplementary Protection Certificates for FLONASE SENSIMIST ALLERGY RELIEF
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C011/2008 | Ireland | ➤ Sign Up | SPC011/2008: 20081105, EXPIRES: 20230110 |
| 429 | Luxembourg | ➤ Sign Up | 91429, EXPIRES: 20230111 |
| 1305329/01 | Switzerland | ➤ Sign Up | PRODUCT NAME: FLUTICASON FUROAT; REGISTRATION NUMBER/DATE: SWISSMEDIC 57968 19.12.2007 |
| C0067 | France | ➤ Sign Up | PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
